Monoclonal Antibody for RSV Prevention Monoclonal Antibody for RSV Prevention

Monoclonal Antibody for RSV Prevention

Available through May 31, 2026

Monoclonal Antibody for RSV Prevention

Protect infants from RSV infection and reduce the severity of symptoms with Nirsevimab, a monoclonal antibody for RSV prevention. This immunization provides ready-made RSV-specific antibodies, enabling the body to fight the virus immediately and safely.

Effectiveness of Monoclonal Antibody for RSV Prevention (Nirsevimab) in Infants:

  • Reduces the risk of RSV infection by up to 79.5%
  • Lowers the risk of hospitalization due to lower respiratory tract infection from RSV by up to 82.7%
  • Decreases ICU ventilator use by 75.3%
  • Provides protection for up to 6 months, covering the peak RSV season
Program Promotion Price
(THB)
Monoclonal Antibody for RSV Prevention (Nirsevimab)  –  1 Dose (50 mg)
(for newborn aged 0-1 month and weight under 5 kg)
11,900
24,100
Monoclonal Antibody for RSV Prevention (Nirsevimab)  –  1 Dose (50 mg) Special price
  • For patients who delivered at Samitivej
  • For Elite Kids / Elite Kids+ vaccine package holders
9,900
Monoclonal Antibody for RSV Prevention (Nirsevimab)  –  1 Dose (100 mg)
(for infants aged over 1 month -12 months and weigh over 5 kg)
15,000
24,100
Monoclonal Antibody for RSV Prevention (Nirsevimab) – 2 Doses (200 mg)
for children aged 12–24 months
29,500
48,200

Since RSV typically spreads during the rainy season, monoclonal antibody injections provide immediate protection and can prevent RSV infection for up to 5 months. 

Terms and Conditions

  • Prices do not include doctor’s fees or hospital service fees
  • Available only to Thai nationals and foreigners residing in Thailand
  • Available for purchase through May 31, 2026; privilege valid until June 30, 2026 

Contraindications for Monoclonal Antibody for RSV Prevention (Nirsevimab)
Do not administer the monoclonal antibody for RSV prevention to children with a history of severe allergic reactions to Nirsevimab or its components, such as arginine or histidine.
Additional Notes:

  • Monoclonal antibody for RSV prevention is important for building immunity in infants during their first year of life
  • Infants aged 0–2 years with underlying health conditions are eligible to receive the injection
  • It can be administered alongside routine childhood vaccines without the need to space them out—even with live vaccines, as it does not interfere with vaccine-induced immunity.
  • Monoclonal antibody for RSV prevention can be given at the same time as other vaccines, as long as each is injected at a different site.